earnings
confidence high
sentiment neutral
materiality 0.70
Fulgent Genetics reports Q4 2024 core revenue up 14% YoY to $76.0M; full year core revenue up 7% to $281.2M
Fulgent Genetics, Inc.
- Full year total revenue $283.5M; core revenue (ex-COVID) grew 7% to $281.2M.
- GAAP net loss of $42.7M ($1.41 per share) for FY 2024; non-GAAP income $15.0M ($0.49 per share).
- Q4 2024 total revenue $76.2M; core revenue up 14% to $76.0M; GAAP loss $5.9M, non-GAAP income $1.2M.
- Ended 2024 with $828.6M cash & investments ($26.87/share); cash from ops $21.1M.